SYK
Stryker Corporation351.69
-3.62-1.02%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A boosts growth confidence, details launches
Q&A reinforced prepared remarks on stellar 2025 results and 8-9.5% 2026 organic growth guidance, but management voiced modestly firmer conviction—citing Mako's order book and installations—deeming 10% achievable. MedSurg's outperformance stems from sales force splits, tuck-ins like Nico, and innovations, with more planned. Trauma/extremities softened on comps and foot/ankle weakness, vascular ischemic hit by rivals, yet new Encompass ankle and Broadway catheter signal rebounds. Spencer Stiles' promotion to President/COO bolsters leadership depth. Mako 4 transition proved a home run. Bullish tone persists; watch tuck-in M&A and EU MDR relief for international catch-up.
Key Stats
Market Cap
134.49BP/E (TTM)
46.27Basic EPS (TTM)
7.60Dividend Yield
0.01%Recent Filings
8-K
Cyber incident contained
Stryker updated on its March cybersecurity incident, confirming with Palo Alto Networks Unit 42 that the threat actor's non-spreading malicious file is contained, with no evidence of access to customer or partner systems. Corporate network disruptions hit Microsoft environment and operations, but manufacturing is ramping up. Investigation ongoing; material impact undetermined. No persistent threats remain.
8-K
Cyber incident disrupts operations
Stryker disclosed an ongoing cybersecurity incident, first reported March 11, 2026, disrupting its Microsoft environment and global operations including order processing, manufacturing, and shipping. Patient services and connected products remain unaffected. Investigation continues; full scope and impacts unknown. Disruptions threaten revenue and operations.
8-K
Cyber incident disrupts systems
Stryker disclosed a cybersecurity incident on March 11, 2026, disrupting its global Microsoft environment and certain operations. The company activated its response plan with external experts, believes the threat contained with no ransomware detected, yet full restoration timeline remains unknown. Business continuity measures support customers. Investigation ongoing; material impacts undetermined.
10-K
FY2025 results
Stryker drove FY2025 net sales to $25.1B, up 11.2% y/y as reported and 10.7% in constant currency, with MedSurg and Neurotechnology surging 15.7% to $15.6B on Vascular's 50.6% leap post-Inari acquisition while Orthopaedics grew 4.3% to $9.5B despite Spinal Implants divestiture. Q4 accelerated the momentum, posting $7.2B sales—its strongest quarter—powered by procedural volume ramps across segments. Gross margins ticked to 64.0% on pricing and volume; operating income hit 19.5%. $5.0B Inari deal boosted debt to $15.9B yet cash flow swelled to $5.0B; $1.3B dividends paid, no buybacks. Supply chain disruptions threaten quarterly momentum.
8-K
Stryker's strong 2025 results
Stryker crushed Q4 and full-year 2025 with net sales up 11.4% to $7.2B and 11.2% to $25.1B, organic growth at 11.0% and 10.3%. Adjusted operating margins expanded 100 bps to 30.2% and 26.3%, driving adjusted EPS higher by 11.5% to $4.47 and 11.8% to $13.63. Momentum strong. Guides 2026 organic sales 8.0-9.5%, adjusted EPS $14.90-$15.10.
BRKR
Bruker Corporation
44.96-0.71
BSX
Boston Scientific Corporation
92.95+0.76
CNMD
CONMED Corporation
39.20-1.12
DYNT
Dynatronics Corp.
0.04+0.00
EW
Edwards Lifesciences Corporatio
85.32+1.94
KIDS
OrthoPediatrics Corp.
17.91-0.08
MDT
Medtronic plc.
97.72-0.85
OFIX
Orthofix Medical Inc.
15.55-0.16
SNN
Smith & Nephew SNATS, Inc.
32.31+0.08
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52